IDEXX Laboratories, Inc. vs McDonald's Corp — how do they compare? IDEXX Laboratories, Inc. trades at $512.76 (market cap $40.43B), while McDonald's Corp trades at $236.53 (market cap $167.64B). The key difference: McDonald's Corp is far larger — about 4.1× IDEXX Laboratories, Inc.'s market cap, and McDonald's Corp pays a 3.26% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and McDonald's Corp for 164 Days on average.
| IDXX | MCD | |
|---|---|---|
Market Cap | $40.43B | $167.64B |
Volume | 692,164 | 11,320,306 |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $341.06 |
52-Week Low | $504.70 | $230.88 |
Typical Hold Time | 46 Days | 164 Days |
Enterprise Value | $41.32B | $221.41B |
Dividend Yield | — | 3.26% |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $506.67, down 1.7% on the day, with technical indicators showing bearish momentum despite strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $4.27 exceeding expectations of $3.94. Recent developments include the acquisition of CoVetAI to enhance veterinary workflow intelligence and expansion of diagnostic testing platforms internationally. Revenue growth remains robust at $4.3 billion for 2025, with net income margins exceeding 25%.
The stock presents a compelling growth story with strong profitability metrics and analyst consensus pointing to significant upside potential (average price target $665). However, current technical weakness and premium valuations (P/E 36.06) create near-term headwinds. Key risks include foreign exchange pressures and potential slowdown in U.S. veterinary visits, while institutional ownership trends show mixed positioning among major funds.
McDonald's (MCD) trades at $230.88, down 0.68% on the day, with a bearish technical signal from moving averages. The company shows steady revenue growth, reaching $26.89B in 2025, and has consistently beaten EPS estimates in recent quarters. Recent news highlights a new global growth strategy, 'McDonald's NEXT', focusing on automation and improved customer experience to counter competitive pressures and attract diners.
The outlook is mixed: strong fundamentals and a 58.7% analyst buy rating support upside to the $284.70 consensus target, but technical weakness and inflation-driven cost pressures pose near-term risks. The stock offers value through its dividend and defensive profile, yet investors must weigh execution risks of the new strategy against its long-term growth potential.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →